| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Toni K Choueiri | |
| Javid Moslehi | |||
| Steven M Bair | |||
| P2860 | cites work | Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation | Q22004269 |
| Regulation of endothelium-derived nitric oxide production by the protein kinase Akt | Q22010149 | ||
| Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation | Q22010150 | ||
| Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker | Q24595773 | ||
| Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment | Q24657761 | ||
| Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension | Q26826864 | ||
| Tumor angiogenesis: therapeutic implications | Q27860595 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab | Q28219257 | ||
| Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling | Q46158906 | ||
| Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma | Q46329140 | ||
| Home blood-pressure monitoring in patients receiving sunitinib | Q46825569 | ||
| Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. | Q52524245 | ||
| Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. | Q53087417 | ||
| Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. | Q54151586 | ||
| Reversibility of capillary density after discontinuation of bevacizumab treatment | Q57790016 | ||
| Sunitinib-Induced Systemic Vasoconstriction in Swine Is Endothelin Mediated and Does Not Involve Nitric Oxide or Oxidative Stress | Q57816403 | ||
| The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules | Q68085294 | ||
| Vascular permeability factor, an endothelial cell mitogen related to PDGF | Q69116052 | ||
| Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells | Q73138700 | ||
| Cooperation between VEGF and TNF-alpha is necessary for exposure of active tissue factor on the surface of human endothelial cells | Q74598454 | ||
| Reversible cardiomyopathy associated with sunitinib and sorafenib | Q82218514 | ||
| Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes | Q82656539 | ||
| Underestimating cardiac toxicity in cancer trials: lessons learned? | Q83756750 | ||
| The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system | Q84353342 | ||
| Vascular endothelial growth factor is a secreted angiogenic mitogen | Q28646475 | ||
| Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia | Q29615916 | ||
| Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid | Q29617640 | ||
| Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. | Q30492863 | ||
| Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation | Q33308481 | ||
| Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor | Q33339837 | ||
| Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice | Q33381903 | ||
| Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials. | Q33392652 | ||
| Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials | Q33795896 | ||
| Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors | Q33828690 | ||
| Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src | Q33871655 | ||
| Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis | Q34626720 | ||
| Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy | Q34627959 | ||
| Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors | Q34803030 | ||
| Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans | Q36100725 | ||
| Transgenic system for conditional induction and rescue of chronic myocardial hibernation provides insights into genomic programs of hibernation. | Q36423488 | ||
| Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis | Q37067792 | ||
| Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib | Q37098098 | ||
| Cardiotoxicity of the new cancer therapeutics--mechanisms of, and approaches to, the problem | Q37212411 | ||
| Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis | Q37254387 | ||
| Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis | Q37328873 | ||
| Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression | Q37353319 | ||
| Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials | Q37600496 | ||
| Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials | Q37692420 | ||
| Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials | Q37721064 | ||
| Increased Risk of Serious Hemorrhage with Bevacizumab in Cancer Patients: A Meta-Analysis | Q37807240 | ||
| Benefit-risk assessment of bevacizumab in the treatment of breast cancer. | Q37963955 | ||
| Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase | Q39889569 | ||
| Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells | Q41144930 | ||
| Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity | Q41292409 | ||
| Reciprocal relation between VEGF and NO in the regulation of endothelial integrity | Q42442693 | ||
| Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase | Q42450205 | ||
| Dual effects of heparin on VEGF binding to VEGF receptor-1 and transduction of biological responses | Q42450827 | ||
| Isolation of a tumor factor responsible for angiogenesis | Q42835506 | ||
| Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels | Q42928512 | ||
| Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies | Q43559046 | ||
| Congestive heart failure risk in patients with breast cancer treated with bevacizumab. | Q44082273 | ||
| Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. | Q44454368 | ||
| Ligand-independent activation of vascular endothelial growth factor receptor 2 by fluid shear stress regulates activation of endothelial nitric oxide synthase | Q44534254 | ||
| Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. | Q44741318 | ||
| P433 | issue | 4 | |
| P921 | main subject | angiogenesis inhibitor | Q574834 |
| P304 | page(s) | 104-113 | |
| P577 | publication date | 2013-01-02 | |
| P1433 | published in | Trends in Cardiovascular Medicine | Q1850265 |
| P1476 | title | Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives | |
| P478 | volume | 23 |
| Q36051199 | Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. |
| Q28397726 | Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis |
| Q36836294 | Cancer and Its Association With the Development of Coronary Artery Calcification: An Assessment From the Multi-Ethnic Study of Atherosclerosis |
| Q36891574 | Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery |
| Q64117212 | Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association |
| Q44228500 | Cardio-oncology: it takes two to translate |
| Q34042984 | Cardiovascular disease in adult survivors of childhood cancer |
| Q38204169 | Claims analysis of hypertension occurrence, severity changes and patterns of antihypertensive use in cancer patients receiving vascular endothelial growth factor inhibitors. |
| Q34943606 | Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. |
| Q36814771 | Drug target identification using network analysis: Taking active components in Sini decoction as an example |
| Q89565160 | Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib |
| Q38132645 | Emerging paradigms in cardiomyopathies associated with cancer therapies |
| Q57809492 | Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report |
| Q34496687 | High Density Lipoprotein Nanoparticles Deliver RNAi to Endothelial Cells to Inhibit Angiogenesis. |
| Q100533703 | Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib |
| Q40990867 | Ischaemic stroke after exposure to aflibercept: interaction with vitamin K antagonist and/or direct pharmacodynamic effect? |
| Q38845457 | Late Cardiotoxicity: Issues for Childhood Cancer Survivors |
| Q53117997 | Lung cancer as a cardiotoxic state: a review. |
| Q89357784 | Management of VEGF-Targeted Therapy-Induced Hypertension |
| Q35562745 | Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers |
| Q47681122 | Out of the frying pan and into the fire: damage-associated molecular patterns and cardiovascular toxicity following cancer therapy |
| Q58761411 | Ponatinib Activates an Inflammatory Response in Endothelial Cells via ERK5 SUMOylation |
| Q48274997 | Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials. |
| Q46562954 | Preserved endothelial progenitor cell angiogenic activity in African American essential hypertensive patients |
| Q26765210 | Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib |
| Q38581171 | Ramucirumab: A Review in Advanced Gastric Cancer |
| Q35691234 | Risk of treatment-related mortality with sorafenib in cancer patients: a meta-analysis of 20 randomly controlled trials : Risk of sorafenib-associated death |
| Q37729290 | The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase Inhibitors |
| Q38904546 | The Role of Imaging with Cardiac Computed Tomography in Cardio-Oncology Patients |
| Q35596957 | Toward a Cancer Drug of Fungal Origin |
| Q36316309 | Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia |
| Q48342585 | Use of Antihypertensive Drugs in Neoplastic Patients |
| Q38823143 | Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing? |
| Q26766269 | Vascular Complications of Cancer Chemotherapy |
Search more.